Can Spinal Muscular Atrophy Be Screened by IVF in Kyrgyzstan? - Genetic Disease PGT Testing Guide

AI Summary

Main Content Begins

1. Real Consultation Scenario: The Dilemma of SMA Carrier Couples

A couple, the wife aged 35 and the husband aged 37, are both carriers of Spinal Muscular Atrophy (SMA) (heterozygous deletion of the SMN1 gene). They previously completed genetic counseling domestically and were informed that natural pregnancy carries a 25% chance of having an affected child and a 50% chance of having a carrier. The couple plans to use IVF technology to screen for healthy embryos. Considering the convenience and cost of overseas medical treatment, they have turned their attention to Kyrgyzstan. Their core questions are: Can reproductive centers in Kyrgyzstan perform embryo screening for SMA? Is the technology reliable? What is the process?

Such inquiries have increased significantly in the past two years, reflecting the clear desire of carrier couples for genetic prevention, while also exposing a blind spot in understanding the technical capabilities of overseas reproductive centers. The following content analyzes this from four perspectives: technical principles, national differences, hospital evaluation, and process details.

2. Direct Answer to the Question: Feasibility of SMA PGT-M Screening in Kyrgyzstan

Conclusion: Some centers can, but each must be verified individually.

The causative gene for Spinal Muscular Atrophy is clearly identified (SMN1, located at 5q13.2). It is a single-gene disorder and can theoretically be prevented using PGT-M (Preimplantation Genetic Testing for Monogenic Diseases) technology. Assisted reproductive technology in Kyrgyzstan began developing after 2010, centered in the capital Bishkek. Currently, about 5-6 reproductive centers offer IVF services. Among them, approximately half have PGT (Preimplantation Genetic Testing) capabilities, but fewer centers can independently perform single-gene disease testing (PGT-M) as opposed to only chromosomal aneuploidy screening (PGT-A).

Specifically for SMA screening, the following conditions must be met:

• Laboratory with a single-gene disease testing platform: Including capabilities for genetic probe design, single-cell whole genome amplification, Sanger sequencing or NGS (Next-Generation Sequencing) analysis. Some centers send embryo biopsy samples to third-party genetic laboratories in Russia or Turkey, extending the cycle by 1-2 weeks.
• Genetic counseling and informed consent: Requires providing SMN1 gene test reports for both partners (must be issued by a domestic top-tier hospital or authoritative testing institution), and the center's geneticist must assess the feasibility of the loci.
• Embryo biopsy technology: Trophectoderm biopsy at the blastocyst stage (day 5-6 blastocyst) is the current standard. The center must have a stable laser biopsy system and embryo cryopreservation and thawing capabilities.

If a center can only provide PGT-A (chromosomal number screening), it cannot perform genetic diagnosis for SMA. Therefore, "being able to do third-generation IVF" does not equal "being able to do single-gene disease screening," which is the most easily confused concept in consultations.

3. Why This Issue Arises: The Genetic Mechanism of SMA and the Principle of PGT-M

3.1 The Genetic Nature of SMA

Spinal Muscular Atrophy is an autosomal recessive genetic disease caused by mutations in the SMN1 gene (Survival Motor Neuron 1), leading to a deficiency of the SMN protein. Approximately 95% of SMA patients have a homozygous deletion of exon 7 in the SMN1 gene. Carriers (heterozygotes) do not develop the disease themselves, but if both partners are carriers, their offspring have a 1/4 chance of being affected, a 1/2 chance of being a carrier, and a 1/4 chance of being completely normal.

The core logic of PGT-M is: before embryo implantation, 3-5 trophectoderm cells are obtained via biopsy, DNA is extracted, and the copy number of the SMN1 gene is analyzed to distinguish between normal, carrier, and affected embryos. Only embryos with a normal copy number (or carrier embryos, depending on the couple's wishes and ethical framework) are transferred.

3.2 Why Not All PGT Centers Can Perform SMA Screening

PGT-M is more challenging than PGT-A (chromosomal screening): it requires designing specific genetic probes for each family (usually taking 4-8 weeks), requires prior knowledge of the family's genetic background (proband sample or couple's genetic reports), and demands significantly higher genetic analysis capabilities from the laboratory. Reproductive centers in Kyrgyzstan often use "third-generation IVF" as a marketing point, but some centers actually only have PGT-A capabilities or rely on external laboratories for PGT-M.

4. Doctor's Perspective: How to Determine if a Center Can Perform SMA Screening

From a reproductive medicine perspective, evaluating an overseas center's ability to screen for single-gene diseases should not rely solely on its website or brochures. The following points are professional criteria for assessment:

Evaluation Dimension	Specific Content	Key Questions to Ask
Genetic Testing Platform	Whether it has an NGS sequencing or SNP chip platform; experience with single-cell amplification; whether probe design is in-house or outsourced	"How long does SMA probe design take? Which method is used?"
Genetic Counseling Team	Whether it has a full-time genetic counselor or collaborating geneticist; whether Chinese or English consultation services are provided	"Who interprets the genetic report? Is remote consultation possible?"
Embryo Biopsy Experience	Number of PGT cycles per year; blastocyst survival rate after biopsy; whether laser-assisted hatching is performed	"How many PGT-M cases were done last year?"
Success Rate and Risks	Rate of continued embryo development after biopsy; diagnostic accuracy (≥95%); misdiagnosis rate and verification mechanism	"How are cases of diagnostic failure or uncertainty handled?"

In actual communication, it is advisable to request de-identified data from previous single-gene disease cases (e.g., number of diseases tested, diagnostic success rate, pregnancy outcomes after transfer) rather than relying solely on verbal promises of "we can do it."

5. Differences Between Countries and Regions: Kyrgyzstan vs. Other Destinations

Choosing Kyrgyzstan for SMA screening requires a horizontal evaluation within the global landscape of assisted reproduction. The following comparison is based on public information and practitioner feedback:

Country/Region	PGT-M Technical Maturity	Experience with SMA Testing	Reference Cost (RMB)	Main Limitations
Kyrgyzstan	Moderate to low, PGT-M is in early development	Few cases, relies on external genetic laboratories	70,000 - 100,000 (including PGT-M)	Weak genetic counseling; language communication costs; policy stability
Turkey	Relatively high, mature PGT centers in Istanbul/Ankara	Rich experience in single-gene disease testing, SMA cases common	120,000 - 180,000 (including PGT-M)	Requires connecting flights; some centers are overly commercialized
Thailand	High, mature PGT platforms at centers like Jetanin/BNH	Well-established single-gene disease testing system, stable genetic counseling team	140,000 - 200,000 (including PGT-M)	Policy fluctuations in recent years; requires booking 3 months in advance
Mainland China	High, limited to qualified tertiary reproductive centers	SMA screening is a routine PGT-M procedure	50,000 - 80,000 (including PGT-M)	Must meet medical indications; waiting period 6-12 months

Kyrgyzstan's core advantages are relatively lower costs and visa convenience (e-visa, 30-day stay), but the trade-off is lower maturity in technical aspects and depth of genetic counseling compared to Turkey or Thailand. For a disease like SMA, where the causative gene is clear and probe design is relatively mature, as long as the center has basic PGT-M capabilities and connects with a reliable genetic laboratory, the technical success rate is not low. The key lies in thorough pre-cycle genetic confirmation and communication of the plan.

6. Practical Process: Roadmap from Genetic Testing to Embryo Transfer

Below is a standardized SMA-PGT cycle process applicable to most centers in Kyrgyzstan capable of this technology:

6.1 Preliminary Preparation (Completed Domestically)

• SMN1 gene testing for both partners: Report issued by a domestic top-tier hospital or third-party testing institution (e.g., BGI, Berry Genomics) clearly indicating the mutation type (deletion/point mutation).
• Genetic counseling and probe feasibility assessment: Send the report to the target center for the genetic team to confirm if a probe can be designed and inform the expected diagnostic rate (usually ≥95%).
• Documents and registration: Passport (valid), marriage certificate (translated and notarized), translated copies of previous medical records.

6.2 Cycle in Kyrgyzstan (Approximately 35-45 Days)

• Pre-cycle tests: Female: AMH, hormone profile, antral follicle count; Male: semen analysis; Infectious disease screening for both.
• Ovarian stimulation and egg retrieval: Approximately 10-14 days of stimulation, followed by egg retrieval and ICSI (Intracytoplasmic Sperm Injection).
• Blastocyst culture and biopsy: Culture to day 5-6 post-fertilization. Trophectoderm biopsy is performed on blastocysts meeting biopsy criteria (usually ≥3BC).
• Genetic testing: Biopsy samples are sent to the laboratory for whole genome amplification and SMN1 gene copy number analysis (results in approximately 2-4 weeks).
• Frozen embryo transfer: Based on genetic results, a normal embryo is selected for transfer after endometrial preparation (natural cycle or hormone replacement cycle).

6.3 Post-Transfer Follow-up

• Blood test (β-hCG) 12-14 days after transfer to confirm pregnancy.
• After clinical pregnancy, amniocentesis is recommended at 18-22 weeks of gestation to verify the embryo's genotype (standard verification procedure after PGT-M).

7. Timeline: How Long Does the Entire Cycle Take

From the first consultation to the end of the transfer, it is recommended to allow 4-6 months. The breakdown is as follows:

Stage	Time	Notes
Preliminary genetic testing + genetic counseling	2-4 weeks	Probe design can be done concurrently
Visa, documents, travel arrangements	2-3 weeks	Kyrgyzstan e-visa takes 3-5 working days
Ovarian stimulation + egg retrieval + blastocyst culture	3-4 weeks	Requires continuous stay in the country
Genetic testing (PGT-M)	3-5 weeks	May be longer if sent to a third-party lab
Endometrial preparation + transfer	2-4 weeks	Can prepare back home or complete locally

It is important to note that probe design is the time bottleneck. If the center needs to send samples to a genetic laboratory in Russia or Europe, logistics and testing time may increase by 1-2 weeks. It is recommended to complete probe design and confirm feasibility before starting the cycle to avoid the predicament of being unable to test after ovarian stimulation.

8. Factors Influencing Cost: Why the Price Difference is So Large

The cost of an SMA-PGT cycle in Kyrgyzstan is approximately 70,000 to 100,000 RMB, but the final amount depends on the following variables:

• Genetic testing model: In-house platform vs. outsourced laboratory. In-house platforms are cheaper (about 10,000-20,000 RMB), while outsourcing involves logistics and third-party service fees (about 30,000-40,000 RMB).
• Number of embryos and biopsies: When the number of biopsied embryos exceeds 5-6, some centers charge an additional testing fee "per embryo."
• Need for sperm/egg donation: If third-party gametes are involved, costs increase additionally.
• Number of transfer cycles: Some centers include one transfer in the fee; if the first transfer fails, subsequent transfers require separate payment.
• Translation and coordination services: The service fee for a Chinese coordinator is usually calculated separately (about 10,000-20,000 RMB).

It is advisable to obtain a written confirmation of what is included in the fee before signing the contract: whether it includes probe design fee, biopsy fee, genetic testing fee, one transfer fee, and embryo freezing fee. Avoid hidden costs like "testing fee not included" or "transfer fee extra."

9. Details Most Easily Overlooked

10. Common Pitfalls to Avoid

11. Frequently Asked Questions (FAQ)

12. Practitioner Observation: Real Cases and Precautions for SMA Screening

In a case we encountered, a couple completed an SMA-PGT cycle at a center in Bishkek. 12 eggs were retrieved, 5 blastocysts formed, and after biopsy, 2 were found to be completely normal (double copy of SMN1), 1 was a carrier, and 2 were abnormal (homozygous deletion). A normal embryo was transferred, resulting in a successful pregnancy. Amniotic fluid verification at 20 weeks confirmed the PGT-M results. Key success factors for this case included: complete preliminary genetic reports, smooth probe design, stable biopsy technique at the center, and genetic testing completed within 4 weeks.

However, there are also counterexamples. A couple traveled to Kyrgyzstan without confirming whether the center had PGT-M capabilities. After starting the cycle and egg retrieval, they discovered the center could only perform PGT-A and could not test for SMA. They ultimately had to freeze the embryos and seek testing elsewhere, incurring additional time and costs. This lesson underscores that: technical capability verification must be done upfront and confirmed in writing.

From an industry trend perspective, assisted reproductive technology in Kyrgyzstan is rapidly improving. Some centers have begun collaborating with genetic laboratories in Russia and Kazakhstan, and the accessibility of single-gene disease testing is improving year by year. However, for a disease with a clearly identified causative gene like SMA, the safety baseline is: there must be a clear probe design plan and genetic counseling process; otherwise, one should not proceed with the cycle rashly.

---

End: Risk Reminder